Bioxcel Therapeutics's market cap is currently ―. The company's EPS TTM is $-5.182; its P/E ratio is -0.40; Bioxcel Therapeutics is scheduled to report earnings on August 6, 2024, and the estimated EPS forecast is $-0.74. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 376.00K	$ 341.00K	$ 457.00K	$ 206.00K	$ 238.00K
Gross Profit	$ -337.00K	$ -171.00K	$ 431.00K	$ 197.00K	$ 229.00K
EBIT	$ -18.82M	$ -47.23M	$ -50.26M	$ -49.43M	$ -53.31M
EBITDA	$ -18.15M	$ -46.78M	$ -49.82M	$ -49.02M	$ -52.91M
Net Income Common Stockholders	$ -22.26M	$ -50.49M	$ -53.52M	$ -52.80M	$ -54.81M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 65.22M	$ 89.96M	$ 127.55M	$ 165.52M	$ 193.72M
Total Assets	$ 73.70M	$ 100.45M	$ 140.10M	$ 179.10M	$ 205.85M
Total Debt	$ 101.04M	$ 99.62M	$ 97.46M	$ 95.77M	$ 93.84M
Net Debt	$ 35.82M	$ 9.66M	$ -30.08M	$ -69.76M	$ -99.89M
Total Liabilities	$ 130.21M	$ 141.06M	$ 134.23M	$ 127.10M	$ 129.08M
Stockholders Equity	$ -56.51M	$ -40.61M	$ 5.86M	$ 53.01M	$ 76.78M
Cash Flow	-
Free Cash Flow	$ -26.86M	$ -37.58M	$ -38.23M	$ -52.35M	$ -38.64M
Operating Cash Flow	$ -26.86M	$ -37.58M	$ -38.21M	$ -52.35M	$ -38.64M
Investing Cash Flow	-	-	$ -20.00K	-	-
Financing Cash Flow	$ 2.12M	-	$ 250.00K	$ 24.15M	$ 50.00K

Currency in USD

Bioxcel Therapeutics Earnings and Revenue History

Income Statement >

Bioxcel Therapeutics Debt to Assets

Balance Sheet >

Bioxcel Therapeutics Cash Flow

Cash Flow >

Bioxcel Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing